2026 Q1 -tulosraportti
57 päivää sitten
‧1 t 2 min
18,00 DKK/osake
Viimeisin osinko
5,19%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·16 t sittenI finished writing my SOP for HHX 3.G last week, and I would love to share it with you all here on the forum. I have provided a summary of the report below. The comment section will go deeper into the numbers: Summary: This report investigates why Coloplast's stock price has fallen significantly since 2021, and whether the stock constitutes a good investment opportunity today. The report answers this through a characteristic of Coloplast, an account of the fundamental analysis theorists, Benjamin Graham, Warren Buffett and Philip Fisher, as well as a qualitative and quantitative fundamental analysis of the company, supplemented by a small comparative analysis against the competitor Smith & Nephew. Coloplast is a Danish medtech company with market leader status in several of its core markets and steadily growing revenue. The stock price drop of 63.8% from November 2021 to March 2026 is due to a combination of external factors such as rising interest rates and Chinese protectionism, but primarily internal fundamental problems. The Strive25 strategy's acquisition of Atos Medical and Kerecis for a total of DKK 25 billion strongly pressured margins and financial costs, and management's lack of execution power resulted in the firing of CEO Kristian Villumsen in May 2025. Looking ahead, the Gordon Growth Model indicates an intrinsic value far above the current price, and a forward P/E of 18,70 signals an expectation of rising future earnings. The new CEO Gavin Wood and the more focused Impact4 strategy send positive signals. The overall assessment is that Coloplast constitutes a potential investment opportunity for the long-term and risk-tolerant investor, while the large debt burden and management uncertainty make the stock unsuitable for the more cautious.·16 t sittenYou are welcome to send me an email if you are interested in reading the full report. I will see if I can send a copy. Email: andreasbirkmose@gmail.com
·29.3.I honestly don't understand why COLOPLAST is so low priced ❗️ 📈 The new CEO is in place 📈 The acquisition of quality products for diabetic wound healing and for burns etc. is moving 🤑 forward and is distributed worldwide, not just to the USA market. (Biological wound dressings = Growth) 📈 COLOPLAST is well-cushioned and a safe haven in times of crisis. Summarized and all in all, it is thus a good and safe stock as I see it. I am a happy and confident COLO shareholder when it comes to the future if you ask me. ( LOW PRICE and good return going forward ) It will be fine, calm down. 🏹
·3 päivää sittenAgreed, it all depends on future growth in value creation.- ·24.3.I am currently writing my SOP in 3.G about Coloplast, and will conduct a thorough Fundamental Analysis of the company, based on Quantitative and qualitative data. It will mainly focus on financial statement analysis, stock key figures, strategy, management, future prospects and meeting expectations. I am fortunately enjoying my 2 weeks of productive holiday, and need to submit it on Friday. Afterwards, I can send a summary, and a link to the report here. So please stay updated, those of you who are interested in a thorough fundamental analysis, of a fundamental Danish stock.
·3 päivää sittenFeel free to send / upload an assignment or a sharp resume here...·3 päivää sittenI'll get a post up here during the week, I think. The length was said to be 15-20 standard pages, or around 6-8000 words. I didn't get enough on the analysis, I think myself. So I'll do a bit more on it later. Just so I can take advantage of being well underway with a strong analysis. Two methods I still need to use.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
57 päivää sitten
‧1 t 2 min
18,00 DKK/osake
Viimeisin osinko
5,19%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16 t sittenI finished writing my SOP for HHX 3.G last week, and I would love to share it with you all here on the forum. I have provided a summary of the report below. The comment section will go deeper into the numbers: Summary: This report investigates why Coloplast's stock price has fallen significantly since 2021, and whether the stock constitutes a good investment opportunity today. The report answers this through a characteristic of Coloplast, an account of the fundamental analysis theorists, Benjamin Graham, Warren Buffett and Philip Fisher, as well as a qualitative and quantitative fundamental analysis of the company, supplemented by a small comparative analysis against the competitor Smith & Nephew. Coloplast is a Danish medtech company with market leader status in several of its core markets and steadily growing revenue. The stock price drop of 63.8% from November 2021 to March 2026 is due to a combination of external factors such as rising interest rates and Chinese protectionism, but primarily internal fundamental problems. The Strive25 strategy's acquisition of Atos Medical and Kerecis for a total of DKK 25 billion strongly pressured margins and financial costs, and management's lack of execution power resulted in the firing of CEO Kristian Villumsen in May 2025. Looking ahead, the Gordon Growth Model indicates an intrinsic value far above the current price, and a forward P/E of 18,70 signals an expectation of rising future earnings. The new CEO Gavin Wood and the more focused Impact4 strategy send positive signals. The overall assessment is that Coloplast constitutes a potential investment opportunity for the long-term and risk-tolerant investor, while the large debt burden and management uncertainty make the stock unsuitable for the more cautious.·16 t sittenYou are welcome to send me an email if you are interested in reading the full report. I will see if I can send a copy. Email: andreasbirkmose@gmail.com
- ·29.3.I honestly don't understand why COLOPLAST is so low priced ❗️ 📈 The new CEO is in place 📈 The acquisition of quality products for diabetic wound healing and for burns etc. is moving 🤑 forward and is distributed worldwide, not just to the USA market. (Biological wound dressings = Growth) 📈 COLOPLAST is well-cushioned and a safe haven in times of crisis. Summarized and all in all, it is thus a good and safe stock as I see it. I am a happy and confident COLO shareholder when it comes to the future if you ask me. ( LOW PRICE and good return going forward ) It will be fine, calm down. 🏹·3 päivää sittenAgreed, it all depends on future growth in value creation.
- ·24.3.I am currently writing my SOP in 3.G about Coloplast, and will conduct a thorough Fundamental Analysis of the company, based on Quantitative and qualitative data. It will mainly focus on financial statement analysis, stock key figures, strategy, management, future prospects and meeting expectations. I am fortunately enjoying my 2 weeks of productive holiday, and need to submit it on Friday. Afterwards, I can send a summary, and a link to the report here. So please stay updated, those of you who are interested in a thorough fundamental analysis, of a fundamental Danish stock.·3 päivää sittenFeel free to send / upload an assignment or a sharp resume here...·3 päivää sittenI'll get a post up here during the week, I think. The length was said to be 15-20 standard pages, or around 6-8000 words. I didn't get enough on the analysis, I think myself. So I'll do a bit more on it later. Just so I can take advantage of being well underway with a strong analysis. Two methods I still need to use.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
2026 Q1 -tulosraportti
57 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
18,00 DKK/osake
Viimeisin osinko
5,19%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16 t sittenI finished writing my SOP for HHX 3.G last week, and I would love to share it with you all here on the forum. I have provided a summary of the report below. The comment section will go deeper into the numbers: Summary: This report investigates why Coloplast's stock price has fallen significantly since 2021, and whether the stock constitutes a good investment opportunity today. The report answers this through a characteristic of Coloplast, an account of the fundamental analysis theorists, Benjamin Graham, Warren Buffett and Philip Fisher, as well as a qualitative and quantitative fundamental analysis of the company, supplemented by a small comparative analysis against the competitor Smith & Nephew. Coloplast is a Danish medtech company with market leader status in several of its core markets and steadily growing revenue. The stock price drop of 63.8% from November 2021 to March 2026 is due to a combination of external factors such as rising interest rates and Chinese protectionism, but primarily internal fundamental problems. The Strive25 strategy's acquisition of Atos Medical and Kerecis for a total of DKK 25 billion strongly pressured margins and financial costs, and management's lack of execution power resulted in the firing of CEO Kristian Villumsen in May 2025. Looking ahead, the Gordon Growth Model indicates an intrinsic value far above the current price, and a forward P/E of 18,70 signals an expectation of rising future earnings. The new CEO Gavin Wood and the more focused Impact4 strategy send positive signals. The overall assessment is that Coloplast constitutes a potential investment opportunity for the long-term and risk-tolerant investor, while the large debt burden and management uncertainty make the stock unsuitable for the more cautious.·16 t sittenYou are welcome to send me an email if you are interested in reading the full report. I will see if I can send a copy. Email: andreasbirkmose@gmail.com
- ·29.3.I honestly don't understand why COLOPLAST is so low priced ❗️ 📈 The new CEO is in place 📈 The acquisition of quality products for diabetic wound healing and for burns etc. is moving 🤑 forward and is distributed worldwide, not just to the USA market. (Biological wound dressings = Growth) 📈 COLOPLAST is well-cushioned and a safe haven in times of crisis. Summarized and all in all, it is thus a good and safe stock as I see it. I am a happy and confident COLO shareholder when it comes to the future if you ask me. ( LOW PRICE and good return going forward ) It will be fine, calm down. 🏹·3 päivää sittenAgreed, it all depends on future growth in value creation.
- ·24.3.I am currently writing my SOP in 3.G about Coloplast, and will conduct a thorough Fundamental Analysis of the company, based on Quantitative and qualitative data. It will mainly focus on financial statement analysis, stock key figures, strategy, management, future prospects and meeting expectations. I am fortunately enjoying my 2 weeks of productive holiday, and need to submit it on Friday. Afterwards, I can send a summary, and a link to the report here. So please stay updated, those of you who are interested in a thorough fundamental analysis, of a fundamental Danish stock.·3 päivää sittenFeel free to send / upload an assignment or a sharp resume here...·3 päivää sittenI'll get a post up here during the week, I think. The length was said to be 15-20 standard pages, or around 6-8000 words. I didn't get enough on the analysis, I think myself. So I'll do a bit more on it later. Just so I can take advantage of being well underway with a strong analysis. Two methods I still need to use.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt